Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02477696 |
Recruitment Status :
Active, not recruiting
First Posted : June 23, 2015
Last Update Posted : December 5, 2019
|
Sponsor:
Acerta Pharma BV
Information provided by (Responsible Party):
Acerta Pharma BV
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | March 2021 |
Estimated Study Completion Date : | March 2021 |